Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model

Autor(es)

Chaves, K. C. B. ^{[1, 2]} ; Peron, J. P. S. ^[3] ; Chammas, R. ^[4] ; Turaca, L. T. ^[5] ; Pesquero, J. B. ^[5] ; Braga, M. S. ^{[1, 2]} ; Foguer, K. ^{[1, 2]} ; Schor, N. ^[2] ; Bellini, M. H. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, IPEN CNEN, Dept Biotechnol, BR-05508000 Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Div Nephrol, Dept Med, BR-05508000 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Immunol, ICB 4, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Dept Radiol, Sao Paulo - Brazil

^[5] Univ Fed Sao Paulo, Dept Biophys, BR-05508000 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Cancer Gene Therapy; v. 19, n. 8, p. 558-565, AUG 2012.
• Citações Web of Science: 7

Resumo

One of the greatest challenges in urological oncology is renal cell carcinoma (RCC), which is the third leading cause of death in genitourinary cancers. RCCs are highly vascularized and respond positively to antiangiogenic therapy. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the potential of ES-based antiangiogenic therapy to activate tumor-associated endothelial cells in metastatic RCC (mRCC). Balb/c-bearing Renca cells were treated with NIH/3T3-LendSN or, as a control, with NIH/3T3-LXSN cells. The T-cell subsets and lymphocyte populations of tumors, mediastinal lymph nodes and the spleen were assessed by flow cytometry. The expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was assessed by real-time PCR, flow cytometry and immunohistochemistry analysis. ES gene therapy led to an increase in the percentage of infiltrating CD4-interferon (IFN)-gamma cells (P<0.05), CD8-IFN-gamma cells (P<0.01) and CD49b-tumor necrosis factor-alpha cells (P<0.01). In addition, ES therapy caused an increase at the mRNA level of ICAM-1 (1.4-fold; P<0.01) and VCAM-1 (1.5-fold) (control vs treated group; P<0.001). Through flow cytometry, we found a significant increase in the CD34/ICAM-1 cells (8.1-fold; P<0.001) and CD34/VCAM-1 cells (1.6-fold; P<0.05). ES gene therapy induced a significant increase in both T CD4 and CD8 cells in the lymph nodes and the spleen, suggesting that ES therapy may facilitate cell survival or clonal expansion. CD49b cells were also present in increased quantities in all of these organs. In this study, we demonstrate an antitumor inflammatory effect of ES in an mRCC model, and this effect is mediated by an increase in ICAM-1 and VCAM-1 expression in tumor-associated endothelial cells. (AU)

• Processo FAPESP: 09/12518-9 - Avaliação da expressão de moléculas de adesão (VCAM e ICAM) no carcinoma renal metastático pulmonar de animais submetidos à terapia gênica com a endostatina
• Beneficiário: Karen Cristina Barbosa Chaves
• Modalidade de apoio: Bolsas no Brasil - Mestrado